Полювання вчених на коронавірус SARS-COV-2, що викликає COVID-19: наукові стратегії подолання пандемії
DOI:
https://doi.org/10.15407/visn2020.08.029Ключові слова:
COVID-19 pandemic, SARS-CoV-2 coronavirus, ways of infection, COVID-19 diagnosis, anti-viral immunity, vaccines, models of the epidemic processАнотація
У статті наведено широкий і ґрунтовний аналіз поточної ситуації щодо пандемії COVID-19. Розглянуто питання походження та будови вірусу SARS-CoV-2, шляхів інфікування, особливостей перебігу захворювання, діагностики COVID-19, застосування фармацевтичних препаратів для лікування хвороби, формування імунітету проти SARS-CoV-2, створення вакцин та ефективності протиепідемічних карантинних заходів. Обговорено використання математичних моделей епідемічного процесу та перспектив виходу з карантину.
Посилання
Reimann H.A. Landmark article Dec 24, 1938: An acute infection of the respiratory tract with atypical pneumonia. A disease entity probably caused by a filtrable virus. JAMA. 1984. 251(7): 936–944. DOI: https://doi.org/10.1001/jama.251.7.936
Severe acute respiratory syndrome. https://en.wikipedia.org/wiki/Severe_acute_respiratory_syndrome
Middle East respiratory syndrome. https://en.wikipedia.org/wiki/Middle_East_respiratory_syndrome
COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6
In Ukraine — the first case of coronavirus. Ukrayinska pravda. March 3, 2020 (in Ukrainian). https://www.pravda.com.ua/news/2020/03/3/7242332/
Wee S.-L., McNeil D.G.Jr. China Identifies New Virus Causing Pneumonialike Illness. https://www.nytimes.com/2020/01/08/health/china-pneumonia-outbreak-virus.html
Lu R., Zhao X., Li J. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020. 395(10224): 565–574. DOI: https://doi.org/10.1016/s0140-6736(20)30251-8
Beaudette F.R., Hudson C.B. Cultivation of the virus of infectious bronchitis. J. Am. Vet. Med. Assoc. 1937. 90: 51–58.
Tyrrell D.A., Bynoe M.l. Cultivation of a novel type of common-cold virus in organ cultures. Br. Med. J. 1965. 1(5448): 1467–1470. DOI: https://doi.org/10.1136/bmj.1.5448.1467
Woo P.C., Lau S.K., Huang Y., Yuen K.Y. Coronavirus diversity, phylogeny and interspecies jumping. Exp. Biol. Med. (Maywood). 2009. 234(10): 1117–1127. DOI: https://doi.org/10.3181/0903-mr-94
Derek Wong’s Virology. http://virology-online.com/viruses/CORZA4.htm
Phylogeny of SARS-like betacoronaviruses including novel coronavirus SARS-CoV-2. https://nextstrain.org/groups/blab/sars-like-cov
Davidson H. First Covid-19 case happened in November, China government records show — report. https://www.theguardian.com/world/2020/mar/13/first-covid-19-case-happened-in-november-china-government-records-show-report
Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020. 395(10223): 497–506. DOI: https://doi.org/10.1016/S0140-6736(20)30183-5
Osborne H. Coronavirus Outbreak May Have Started As Early As September, Scientists Say. https://www.newsweek.com/coronavirus-outbreak-september-not-wuhan-1498566
Zhou P., Yang X.L., Wang X.G. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020. 579(7798): 270–273. DOI: https://doi.org/10.1038/s41586-020-2012-7
Readfearn G. How did coronavirus start and where did it come from? Was it really Wuhan’s animal market? https://www.theguardian.com/world/2020/apr/28/how-did-the-coronavirus-start-where-did-it-come-from-how-did-it-spread-humans-was-it-really-bats-pangolins-wuhan-animal-market
Liu P., Jiang J.Z., Wan X.F., Hua Y., Li L., Zhou J., Wang X., Hou F., Chen J., Zou J., Chen J. Are pangolins the intermediate host of the 2019 novel coronavirus (SARS-CoV-2)? PLoS Pathog. 2020. 16(5): e1008421. DOI: https://doi.org/10.1371/journal.ppat.1008421
Andersen K.G., Rambaut A., Lipkin W.I., Holmes E.C., Garry R.F. The proximal origin of SARS-CoV-2. Nat. Med. 2020. 26(4): 450–452. DOI: https://doi.org/10.1038/s41591-020-0820-9
Shinkman P.D. U.S. Spy Agencies Weigh In on Coronavirus Rumors. https://www.usnews.com/news/national-news/articles/2020-04-30/coronavirus-not-man-made-director-of-national-intelligence-says
Sanger D.E. Pompeo Ties Coronavirus to China Lab, Despite Spy Agencies’ Uncertainty. https://www.nytimes.com/2020/05/03/us/politics/coronavirus-pompeo-wuhan-china-lab.html
Pennisi E. How bats have outsmarted viruses — including coronaviruses — for 65 million years. Science. Jul. 22, 2020. DOI: https://doi.org/10.1126/science.abd9595
Scudellari M. The sprint to solve coronavirus protein structures — and disarm them with drugs. Nature News. 15 May 2020. DOI: https://doi.org/10.1038/d41586-020-01444-z
Zhang L., Lin D., Sun X. et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science. 2020. 368(6489): 409–412. DOI: https://doi.org/10.1126/science.abb3405
Wu F., Zhao S., Yu B., Chen Y.M., Wang W., Song Z.G., Hu Y., Tao Z.W., Tian J.H., Pei Y.Y., Yuan M.L., Zhang Y.L., Dai F.H., Liu Y., Wang Q.M., Zheng J.J., Xu L., Holmes E.C., Zhang Y.Z. A new coronavirus associated with human respiratory disease in China. Nature. 2020. 579(7798): 265–269. DOI: https://doi.org/10.1038/s41586-020-2008-3
Schmidt A., Wolff M.H., Weber O. Coronaviruses with special emphasis on first insights concerning SARS. Springer, 2005. 232 p. DOI: https://doi.org/10.1007/b137625
Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.-L., Abiona O., Graham B.S., McLellan J.S. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020. 367(6483): 1260–1263. DOI: https://doi.org/10.1126/science.abb2507
Zhang X., Li Sh., Niu Sh. ACE2 and COVID-19 and the Resulting ARDS. Postgrad. Med. J. 2020. 96(1137): 403–407. https://doi.org/10.1136/postgradmedj-2020-137935
Watanabe Ya., Allen J.D., Wrapp D., McLellan J.S., Crispin M. Site-specific glycan analysis of the SARS-CoV-2 spike. Science. 2020. 369(6501): 330–333. DOI: https://doi.org/10.1126/science.abb9983
Hoffman M. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020. DOI: https://doi.org/10.1016/j.cell.2020.02.052
Sakai K., Ami Y., Tahara M. et al. The Host Protease TMPRSS2 Plays a Major Role in in Vivo Replication of Emerging H7N9 and Seasonal Influenza. Viruses J. Virol. 2014. 88(10): 5608–5616. DOI: https://doi.org/10.1128/JVI.03677-13
Vankadari N., Wilce J.A. Emerging WuHan (COVID-19) Coronavirus: Glycan Shield and Structure Prediction of Spike Glycoprotein and Its Interaction With Human CD26. Emerg. Microbes Infect. 2020. 9(1): 601–604. DOI: https://doi.org/10.1080/22221751.2020.1739565
Wang K., Chen W., Zhou Y.-S. et al. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. bioRxiv. DOI: https://doi.org/10.1101/2020.03.14.988345
Castelvetri L.C., Ojha R., Pedro L.D. et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and provides a possible pathway into the central nervous system. BioRxiv preprint. DOI: https://doi.org/10.1101/2020.06.07.137802
Jia Y., Shen G., Zhang Y., Huang K.-S., Ho H.-Y., Hor W.-S., Yang C.-H., Li C., Wang W.-L. Analysis of the mutation dynamics of SARS-CoV-2 reveals the spread history and emergence of RBD mutant with lower ACE2 binding affinity. BioRxiv. 2020. DOI: https://doi.org/10.1101/2020.04.09.034942
Zhang L., Jackson C.B., Mou H., Ojha A., Rangarajan E.S., Izard T., Farzan M., Choe H. The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. BioRxiv. June 12, 2020. DOI: https://doi.org/10.1101/2020.06.12.148726
Thao T.T.N., Labroussaa F., Ebert N. et al. Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform. Nature. 2020. DOI: https://doi.org/10.1038/s41586-020-2294-9
Sun J., Zhuang Zh., Zheng J. et al. Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment. Cell. 2020. 182: 1–10. DOI: https://doi.org/10.1016/j.cell.2020.06.010
Gaglia M., Lakdawala S. What we do and do not know about COVID-19’s infectious dose and viral load. https://theconversation.com/what-we-do-and-do-not-know-about-covid-19s-infectious-dose-and-viral-load-135991
Wang W., Xu Y., Gao R., Lu R., Han K., Wu G., Tan W. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA. 2020. 323(18): 1843–1844. DOI: https://doi.org/10.1001/jama.2020.3786
Meyerowitz E.A., Richterman A.G., Quick M.P.H. A Summary of the COVID-19 Literature So Far. Medscape. May 18, 2020. https://www.medscape.com/viewarticle/930588
To K.K., Tsang O.T., Chik-Yan Y.C. et al. Consistent detection of 2019 novel coronavirus in saliva. Clinical Infectious Diseases. 2020. DOI: https://doi.org/10.1093/cid/ciaa149
Sex and Coronavirus Disease 2019 (COVID-19). https://www1.nyc.gov/assets/doh/downloads/pdf/imm/covid-sex-guidance.pdf
Mandavilli A. Infected but Feeling Fine: The Unwitting Coronavirus Spreaders. The New York Times. July 9, 2020. https://www.nytimes.com/2020/03/31/health/coronavirus-asymptomatic-transmission.html
Petri W. Infected with the coronavirus but not showing symptoms? A physician answers 5 questions about asymptomatic COVID-19. The Conversation. https://theconversation.com/infected-with-the-coronavirus-but-not-showing-symptoms-a-physician-answers-5-questions-about-asymptomatic-covid-19-137029
van Doremalen N., Bushmaker T., Morris D.H., Holbrook M.G., Gamble A., Williamson B.N., Tamin A., Harcourt J.L., Thornburg N.J., Gerber S.I., Lloyd-Smith J.O., de Wit E., Munster V.J. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N. Engl. J. Med. 2020. 382(16): 1564–1567. DOI: https://doi.org/10.1056/NEJMc2004973
Sungnak W., Huang N., Becavin C., Berg M., Queen R., Litvinukova M., Talavera-Lopez C., Maatz H., Reichart D., Sampaziotis F., Worlock K.B., Yoshida M., Barnes J.L., Lung H.C.A. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat. Med. 2020. 26: 681–687. DOI: https://doi.org/10.1038/s41591-020-0868-6
All Your Coronavirus Questions, Answered. Time. May 8, 2020. https://time.com/5820118/coronavirus-questions-answered/
Lewis D. Is the coronavirus airborne? Experts can’t agree. Nature News. April 2, 2020. https://www.nature.com/articles/d41586-020-00974-w
Harrison L. Speech May Spread More COVID-19 Than Feces. Medscape. 19 May 2020. https://www.medscape.com/viewarticle/930799
Coronavirus: WHO rethinking how Covid-19 spreads in air. BBC News. 8 July 2020. https://www.bbc.com/news/world-53329946
Rapid Expert Consultation on SARS-CoV-2 Survival in Relation to Temperature and Humidity and Potential for Seasonality for the COVID-19 Pandemic (April 7, 2020). https://www.nap.edu/read/25771/chapter/1
Recommendation Regarding the Use of Cloth Face Coverings, Especially in Areas of Significant Community-Based Transmission. https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover.html
Advice on the use of masks in the context of COVID-19. https://www.who.int/publications-detail/advice-on-the-use-of-masks-in-the-community-during-home-care-and-in-healthcare-settings-in-the-context-of-the-novel-coronavirus-(2019-ncov)-outbreak
Estimating the number of infections and the impact of non-pharmaceutical interventions on COVID-19 in 11 European countries. https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2020-03-30-COVID19-Report-13.pdf
Mizutani T. Signal transduction in SARS-CoV-infected cells. Ann. NY Acad. Sci. 2007. 1102: 86–95. DOI: https://doi.org/10.1196/annals.1408.006
Zimmer C. DNA Inherited From Neanderthals May Increase Risk of Covid-19. The New York Times. July 4, 2020. https://www.nytimes.com/2020/07/04/health/coronavirus-neanderthals.html
Osterweil N. Case Fatality Rate for COVID-19 Near 1.4%, Increases With Age. https://www.medscape.com/viewarticle/927870
Rabin R.C. In Italy, Coronavirus Takes a Higher Toll on Men. https://www.nytimes.com/2020/03/20/health/coronavirus-italy-men-risk.html
Wenham C., Smith J., Morgan R. COVID-19: the gendered impacts of the outbreak. Lancet. 2020. 395(10227): 846–848. DOI: https://doi.org/10.1016/S0140-6736(20)30526-2
Coronavirus in NY: Cases, maps, charts and resources. https://www.syracuse.com/coronavirus-ny/
Wadman M. Sex hormones signal why virus hits men harder. Science. 2020: 368(6495): 1038–1039. DOI: https://doi.org/10.1126/science.368.6495.1038
Zaiets K., Padilla R. Coronavirus, diabetes, obesity and other underlying conditions: Which patients are most at risk? https://www.usatoday.com/in-depth/news/2020/04/15/coronavirus-risk-90-patients-had-underlying-conditions/2962721001/
Mallapaty S. Mounting clues suggest the coronavirus might trigger diabetes. https://www.nature.com/articles/d41586-020-01891-8
Tan T., Khoo B., Mills E.G. et al. Association Between High Serum Total Cortisol Concentrations and Mortality From COVID-19. Lancet Diabetes Endocrinol. 2020. 8(8): 659-660. DOI: https://doi.org/10.1016/S2213-8587(20)30216-3
Balfour H. Blood test could identify those most at risk from COVID-19. Drug Target Review. 22 May 2020. https://www.drugtargetreview.com/news/61778/blood-test-could-identify-those-most-at-risk-from-covid-19/
Yan L., Zhang H.-T., Goncalves J. et al. An interpretable mortality prediction model for COVID-19 patients. Nat. Mach. Intell. 2020. 2: 283–288. DOI: https://doi.org/10.1038/s42256-020-0180-7
Yong Sh.J. Vitamin D as an Independent Risk Factor for COVID-19 Death. https://medium.com/microbial-instincts/lack-of-vitamin-d-as-an-independent-risk-factor-for-covid-19-death-82365d0520fa
Fang L., Karakiulakis G., Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? The Lancet. 2020. 8(4): E21. DOI: https://doi.org/10.1016/s2213-2600(20)30116-8
Sama I.E., Ravera A., Santema B.T. et al. Circulating Plasma Concentrations of Angiotensin-Converting Enzyme 2 in Men and Women With Heart Failure and Effects of Renin-Angiotensin-Aldosterone Inhibitors. Eur. Heart J. 2020. 41(19): 1810–1817. DOI: https://doi.org/10.1093/eurheartj/ehaa373
Murray S. New Evidence Concerning Safety of ACE Inhibitors, ARBs in COVID-19. https://www.pharmacytimes.com/news/new-evidence-concerning-safety-of-ace-inhibitors-arbs-in-covid-19
de Simone G. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers. Council on Hypertension of the European Society of Cardiology. 13 Mar 2020. https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang
Radzikowska U., Ding M., Tan G. et al. Distribution of ACE2, CD147, CD26 and Other SARS-CoV-2 Associated Molecules in Tissues and Immune Cells in Health and in Asthma, COPD, Obesity, Hypertension, and COVID-19 Risk Factors. Allergy. 2020. DOI: https://doi.org/10.1111/all.14429
Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf
Liu R., Wang Y., Li J., Han H., Xia Z., Liu F., Wu K., Yang L., Liu X., Zhu C. Decreased T cell populations contribute to the increased severity of COVID-19. Clin. Chim. Acta. 2020. DOI: https://doi.org/10.1016/j.cca.2020.05.019
Ying T., Li W., Dimitrov D.S. Discovery of T-Cell Infection and Apoptosis by Middle East Respiratory Syndrome Coronavirus. J. Infect. Dis. 2016. 213(6): 877–879. DOI: https://doi.org/10.1093/infdis/jiv381
Shoenfeld Y. Corona (COVID-19) time musings: Our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning. Autoimmun. Rev. 2020. 19(6): 102538. DOI: https://doi.org/10.1016/j.autrev.2020.102538
Cascella M., Rajnik M., Cuomo A., Dulebohn S.C., Di Napoli R. Features, Evaluation and Treatment Coronavirus (COVID-19). (Treasure Island (FL): Stat Pearls Publishing, 2020).
Long B., Brady W.J., Koyfman A., Gottlieb M. Cardiovascular complications in COVID-19. The American Journal of Emergency Medicine. 2020. DOI: https://doi.org/10.1016/j.ajem.2020.04.048
Xu L., Liu J., Lu M., Yang D., Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver International. 2020. 40(5): 998–1004. DOI: https://doi.org/10.1111/liv.14435
Riphagen S., Gomez X., Gonzalez-Martinez C., Wilkinson N., Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. The Lancet. 2020. DOI: https://doi.org/10.1016/s0140-6736(20)31094-1
Kwon D. From Headaches to ‘COVID Toes,’ Coronavirus Symptoms Are a Bizarre Mix. Blood clots and inflammation may underlie many of these complications. https://www.scientificamerican.com/article/from-headaches-to-covid-toes-coronavirus-symptoms-are-a-bizarre-mix1/
Carod-Artal F.J. Neurological complications of coronavirus and COVID-19. Revista de Neurologia. 2020. 70(9): 311–322. DOI: https://doi.org/10.33588/rn.7009.2020179
Brooks M. COVID-19 Tied to Wide Range of Neuropsychiatric Complications. Medscape. June 29, 2020. https://www.medscape.com/viewarticle/933136
Cormier Z. How Covid-19 can damage the brain. BBC News. 23 June 2020. https://www.bbc.com/future/article/20200622-the-long-term-effects-of-covid-19-infection
Yasgur B.S. Three Stages to COVID-19 Brain Damage, New Review Suggests. Medscape. June 29, 2020. https://www.medscape.com/viewarticle/933131
Negro F. Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis? Swiss Med. Weekly. 2020. 150: w20249. DOI: https://doi.org/10.4414/smw.2020.20249
Coronavirus disease (COVID-19) technical guidance: Laboratory testing for 2019-nCoV in humans. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance
Summary table of available protocols in this document. https://www.who.int/docs/default-source/coronaviruse/whoinhouseassays.pdf?sfvrsn=de3a76aa_2
SARS-CoV-2 Diagnostic Pipeline. https://www.finddx.org/covid-19/pipeline/
Coronavirus Testing Picks Up in the U.S. Following Slow Start. https://www.diagnosticsworldnews.com/news/2020/03/17/coronavirus-testing-picks-up-in-the-u.s.-following-slow-start
Liuqian L., Shulun H., Wei H. 14% of Recovered Covid-19 Patients in Guangdong Tested Positive Again. https://www.caixinglobal.com/2020-02-26/14-of-recovered-covid-19-patients-in-guangdong-tested-positive-again-101520415.html
Omer S.B., Malani P., Del Rio C. The COVID-19 Pandemic in the US: A Clinical Update. JAMA. 2020. DOI: https://doi.org/10.1001/jama.2020.5788
Parry R.L. Coronavirus patients can't relapse, South Korean scientists believe. https://www.thetimes.co.uk/article/coronavirus-patients-cant-relapse-south-korean-scientists-believe-rkm8zm7d9
Ukraine has developed test systems to detect antibodies to coronavirus. The Day. April, 13, 2020. (in Ukrainian). https://day.kyiv.ua/uk/news/130420-ukrayina-rozrobyla-test-systemy-dlya-vyznachennya-antytil-do-koronavirusu
Sona Nanotech Inc. Buy. http://cdn.ceo.ca.s3-us-west-2.amazonaws.com/1f8c1h6-SONA.SNANF.Initiation.Maxim.040220.pdf
Sheridan C. Fast, portable tests come online to curb coronavirus pandemic. https://www.nature.com/articles/d41587-020-00010-2
Fletcher E.R., Vijay S.L. New COVID-19 Rapid Diagnostic Approved On ‘GeneXpert’ TB Platform; Could Pave Way For More Testing In Low- & Middle-Income Countries. https://healthpolicy-watch.org/new-covid-19-rapid-test-approved-for-genexpert-tb-platform-could-pave-way-for-more-testing-in-low-middle-income-countries/
Coronavirus (COVID-19) Update: FDA Authorizes First Antigen Test to Help in the Rapid Detection of the Virus that Causes COVID-19 in Patients. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-antigen-test-help-rapid-detection-virus-causes
Sofia 2 SARS antigen FIA. https://www.quidel.com/immunoassays/rapid-sars-tests/sofia-2-sars-antigen-fia
Medical Companies Win Approval for Rapid Coronavirus Tests. https://www.wsj.com/articles/medical-companies-win-approval-for-rapid-coronavirus-tests-11585586147
Broughton J.P., Deng X., Yu G. et al. CRISPR-Cas12-based detection of SARS-CoV-2. Nat. Biotechnol. 2020. DOI: https://doi.org/10.1038/s41587-020-0513-4
Sanders J.M., Monogue M.L., Jodlowski T.Z., Cutrell J.B. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19). JAMA. 2020. 323(18): 1824–1836. DOI: https://doi.org/10.1001/jama.2020.6019
Kupferschmidt K., Cohen J. Race to find COVID-19 treatments accelerates. Science. 2020. 367(6485): 1412–1413. DOI: https://doi.org/10.1126/science.367.6485.1412
Rodell C.B. An ACE therapy for COVID-19. https://stm.sciencemag.org/content/12/541/eabb5676
Leslie M. Biologists invent a new way to fight viruses with llama blood and molecular superglue. https://www.sciencemag.org/news/2020/05/biologists-invent-new-way-fight-viruses-llama-blood-and-molecular-super-glue
Mulligan M.J., Lyke K.E., Kitchin N. et al. Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report. MedRXiv. DOI: https://doi.org/10.1101/2020.06.30.20142570
Ravichandran S., Coyle E.M., Klenow L. et al. Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits. Sci. Transl. Med. 2020. 12(550): eabc3539. DOI: https://doi.org/10.1126/scitranslmed.abc3539
Wang C., Li W., Drabek D., Okba N.M.A., van Haperen R., Osterhaus A.D.M.E., van Kuppeveld F.J.M., Haagmans B.L., Grosveld F., Bosch B.J. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat. Commun. 2020. 11(1): 2251. DOI: https://doi.org/10.1038/s41467-020-16256-y
Chi X., Yan R., Zhang J. et al. A Neutralizing Human Antibody Binds to the N-terminal Domain of the Spike Protein of SARS-CoV-2. Science. 369(6504): 650–655. DOI: https://doi.org/10.1126/science.abc6952
Kramer J. Coronavirus Antibody Therapies Raise Hopes — and Skepticism. Scientific American. May 29, 2020. https://www.scientificamerican.com/article/coronavirus-antibody-therapies-raise-hopes-and-skepticism1/
Yuan M., Wu N.C., Zhu X., et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science. 2020. 368(6491): 630–633. DOI: https://doi.org/10.1126/science.abb7269
Jee Ch. A trial is under way of the first new antibody medicine developed to treat COVID-19. https://www.technologyreview.com/2020/06/01/1002475/trial-new-antibody-medicine-developed-to-treat-covid-19/
Robbiani D.F., Gaebler C., Muecksch F. et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020. DOI: https://doi.org/10.1038/s41586-020-2456-9
Kupferschmidt K. Scientists put survivors’ blood plasma to the test. https://science.sciencemag.org/content/368/6494/922
Etherington D. FDA now allows treatment of life-threatening COVID-19 cases using blood from patients who have recovered. https://techcrunch.com/2020/03/24/fda-now-allows-treatment-of-life-threatening-covid-19-cases-using-blood-from-patients-who-have-recovered/
Demura M., Takada N. Blood plasma treatment for coronavirus set for Japan trial. https://asia.nikkei.com/Business/Health-Care/Blood-plasma-treatment-for-coronavirus-set-for-Japan-trial
Gharbharan A., Jordans C.C.E., van Kessel C.G. et al. Convalescent Plasma for COVID-19. A randomized clinical trial. MedRXiv. 2020. DOI: https://doi.org/10.1101/2020.07.01.20139857
Biopharma encourages citizens who have undergone COVID-19 to become plasma donors for the development of drugs against coronavirus infection. Interfax-Ukraine. May, 8, 2020 (in Ukrainian). https://ua.interfax.com.ua/news/general/661051.html
Lovett S. Coronavirus: Men produce more COVID-19 antibodies than women, study shows. https://www.independent.co.uk/news/health/coronavirus-antibodies-men-women-blood-plasma-donor-a9579441.html
The fight against COVID-19 starts with you. https://www.covig-19plasmaalliance.org/en-US#recruitment
Al Idrus A. Takeda, CSL-led alliance and NIH to test COVID-19 plasma treatment this summer. https://www.fiercebiotech.com/biotech/takeda-csl-led-alliance-and-nih-to-test-plasma-treatment-summer
Cohen E. Human Trials Expected To Start Next Month For Covid-19 Treatment Derived From Cows’ Blood. https://www.sabbiotherapeutics.com/2020/06/16/human-trials-expected-to-start-next-month-for-covid-19-treatment-derived-from-cows-blood/
Sheridan C. Convalescent serum lines up as first-choice treatment for coronavirus. https://www.nature.com/articles/d41587-020-00011-1
The first patient tests new drug against COVID-19. https://www.en.auh.dk/press-room/news-archive/2020/the-first-patient-tests-new-drug-against-covid-19/
Camostat Mesylate in COVID-19 Outpatients. https://clinicaltrials.gov/ct2/show/NCT04353284
Devaux C.A., Rolain J.M., Colson P., Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int. J. Antimicrob Agents. 2020. DOI: https://doi.org/10.1016/j.ijantimicag.2020.105938
Piller C. Former FDA leaders decry emergency authorization of malaria drugs for coronavirus. https://www.sciencemag.org/news/2020/04/former-fda-leaders-decry-emergency-authorization-malaria-drugs-coronavirus
Sciama Y. Is France’s president fueling the hype over an unproven coronavirus treatment? https://www.sciencemag.org/news/2020/04/france-s-president-fueling-hype-over-unproven-coronavirus-treatment
Some Swedish hospitals have stopped using chloroquine to treat COVID-19 after reports of severe side effects. https://www.newsweek.com/swedish-hospitals-chloroquine-covid-19-side-effects-1496368
FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems. https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or
Remdesivir. https://en.wikipedia.org/wiki/Remdesivir#cite_note-:0-4
Yin W., Mao C., Luan X. et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science. 2020. DOI: https://doi.org/10.1126/science.abc1560
Gordon C.J., Tchesnokov E.P., Woolner E., Perry J.K., Feng J.Y., Porter D.P., Gotte M. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J. Biol. Chem. 2020. DOI: https://doi.org/10.1074/jbc.RA120.013679
NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19. https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19
Grein J., Ohmagari N., Shin D. et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N. Engl. J. Med. 2020. DOI: https://doi.org/10.1056/NEJMoa2007016
FDA Allows For 'Emergency Use' of Remdesivir, Experimental Coronavirus Drug. https://time.com/5831062/fda-allows-emergency-use-remdesivir/
Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment
Shimbun A. Japan approves remdesivir for COVID-19 despite uncertainties. http://www.asahi.com/ajw/articles/13358075
Taylor Ph. Remdesivir closes in on receiving first EU approval for treatment for COVID-19. https://www.pmlive.com/pharma_news/remdesivir_closes_in_on_receiving_first_eu_approval_for_treatment_for_covid-19_1343030
Ridgeback Biotherapeutics Announces Launch of Phase 2 Trials Testing EIDD-2801 as Potential Treatment for COVID-19. https://www.businesswire.com/news/home/20200619005038/en/Ridgeback-Biotherapeutics-Announces-Launch-Phase-2-Trials
Lopinavir/ritonavir. https://en.wikipedia.org/wiki/Lopinavir/ritonavir
Choy K.T., Wong A.Y., Kaewpreedee P. et al. Remdesivir, Lopinavir, Emetine, and Homoharringtonine Inhibit SARS-CoV-2 Replication in Vitro. Antiviral Res. 2020. 178: 104786. DOI: https://doi.org/10.1016/j.antiviral.2020.104786
The WHO Solidarity Trial for COVID-19 treatments officially launched in Indonesia. https://www.who.int/indonesia/news/detail/24-04-2020-the-who-solidarity-trial-for-covid-19-treatments-officially-launched-in-indonesia
Li Y., Xie Z., Lin W. et al. An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI). DOI: https://doi.org/10.1101/2020.03.19.20038984
Hung I.F., Lung K.C., Tso E.Y. et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020. DOI: https://doi.org/10.1016/S0140-6736(20)31042-4
WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19. https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19
Kadhim A.A.H., Hadi N.R., Abdulhussein M., Zamil S.T., Zamil S.T. Preprocessing of the Candidate Antiviral Drugs against COVID-19 in Models of SARS cov2 Targets. LPMA. 2020. 106(2): 240.
Rossignol J.F., Maisonneuve H. Nitazoxanide in the treatment of Taenia saginata and Hymenolepis nana infections. Am. J.Trop. Med. Hyg. 1984. 33: 511–512. DOI: https://doi.org/10.4269/ajtmh.1984.33.511
Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z., Hu Z., Zhong W., Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020. 30(3): 269–271. DOI: https://doi.org/10.1038/s41422-020-0282-0
Scientists Identify 69 Drugs to Test Against the Coronavirus. https://www.nytimes.com/2020/03/22/science/coronavirus-drugs-chloroquine.html
Jin Z., Du X., Xu Y. et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020. DOI: https://doi.org/10.1038/s41586-020-2223-y
The Coronavirus Patients Betrayed by Their Own Immune Systems. https://www.nytimes.com/2020/04/01/health/coronavirus-cytokine-storm-immune-system.html
Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection. https://clinicaltrials.gov/ct2/show/NCT04324021
Sagonowsky E. Roche's Actemra falls short in Italian study in early-stage COVID-19 pneumonia. https://www.fiercepharma.com/pharma/roche-s-actemra-fails-italian-study-early-stage-covid-19-pneumonia
Horby P., Lim W.Sh., Emberson J. et al. RECOVERY Collaborative Group Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. MedRXiv. DOI: https://doi.org/10.1101/2020.06.22.20137273
Poperechna D. MOZ vneslo novyy preparat u protokol likuvannya COVID-19. Ukrayinska pravda. June 25, 2020. https://life.pravda.com.ua/health/2020/06/25/241465/
Yasgur B.S. Colchicine Promising in COVID-19 Treatment? https://www.medscape.com/viewarticle/933198
Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. https://www.bmj.com/content/368/bmj.m1086
Ioannou P. Rapid Response: Re: Non-steroidal anti-inflammatory drugs and COVID-19; An ambiguous correlation. https://www.bmj.com/content/368/bmj.m1185/rr-0
Godoy M. Concerned About Taking Ibuprofen For Coronavirus Symptoms? Here's What Experts Say. https://www.npr.org/sections/health-shots/2020/03/18/818026613/advice-from-france-to-avoid-ibuprofen-for-covid-19-leaves-experts-baffled
Klok F.A., Kruip M.J.H.A., van der Meer N.J.M., Arbous M.S., Gommers D.A.M.P.J., Kant K.M., Kaptein F.H.J., van Paassen J., Stals M.A.M., Huisman M.V., Endeman H. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis Research. 2020. DOI: https://doi.org/10.1016/j.thromres.2020.04.013
Tang N., Bai H., Chen X., Gong J., Li D., Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of Thrombosis and Haemostasis. 2020. 18(5): 1094–1099. DOI: https://doi.org/10.1111/jth.14817
Lugovskoy E.V., Kolesnikova I.N., Gritsenko P.G., Komissarenko S.V. Utilization of monoclonal antibodies for the quantification of molecular markers of hemostasis. Journal of Thrombosis and Haemostasis. 2003. 1(Suppl. 1): CD084. (XIX Congress of the International Society on Thrombosis and Haemostasis, Birmingham, UK, July 12-18, 2003.)
Lugovskoy E.V., Gritsenko P.G., Kolesnikova I.N., Zolotareva E.N., Chernishov V.I., Nieuwenhuizen W., Komisarenko S.V. Two monoclonal antibodies to D-dimer-specific inhibitors of fibrin polymerization.Thrombosis Research. 2004. 113(3-4): 251–259. DOI: https://doi.org/10.1016/j.thromres.2004.03.005
Collaboration initiated to develop COVID-19 immunotherapy. https://www.drugtargetreview.com/news/58326/collaboration-initiated-to-develop-covid-19-immunotherapy/
Could T-cell immunotherapy be the answer to COVID-19? https://www.drugtargetreview.com/news/60482/could-t-cell-immunotherapy-be-the-answer-to-covid-19/
Borrell B. New York clinical trial quietly tests heartburn remedy against coronavirus. Science. Apr. 26, 2020. DOI: https://doi.org/10.1126/science.abc4739
Koch S., Pong W. First up for COVID-19: nearly 30 clinical readouts before end of April. https://www.biocentury.com/article/304658/nearly-30-trials-for-covid-19-could-start-to-yield-data-in-the-next-couple-of-months
Lim G.Y. TCM and COVID-19: China conducting trials to test efficacy and safety of traditional herbal interventions. https://www.nutraingredients-asia.com/Article/2020/04/06/TCM-and-COVID-19-China-conducting-trials-to-test-efficacy-and-safety-of-traditional-herbal-interventions
Chapin E. Artemisia Annua Could Be Promising Treatment for COVID-19. https://uknow.uky.edu/research/artemisia-annua-could-be-promising-treatment-covid-19
Wadman M. Can interferons stop COVID-19 before it takes hold? Science. 2020: 369(6500): 125–126. DOI: https://doi.org/10.1126/science.369.6500.125
Kupferschmidt K. These Drugs Don’t Target the Coronavirus – They Target Us. https://www.sciencemag.org/news/2020/04/these-drugs-don-t-target-coronavirus-they-target-us
Lipsitch M. Who Is Immune to the Coronavirus? https://www.nytimes.com/2020/04/13/opinion/coronavirus-immunity.html
COVID-19 Antibodies Can Disappear After 2-3 Months, Study Shows. https://www.medscape.com/viewarticle/932671
To K.K.-W., Cheng V.Ch.-Ch., Cai J.-P. et al. Seroprevalence of SARS-CoV-2 in Hong Kong and in residents evacuated from Hubei province, China: a multicohort study. Lancet Microbe. 2020. DOI: https://doi.org/10.1016/S2666-5247(20)30053-7
Dr. Fauci Explains The Timeline And Risks Of Creating A COVID-19 Vaccine. MSNBC. https://www.youtube.com/watch?v=ZrWAqpPGAxQ
CEPI. https://cepi.net/covid-19/
Berkley S. COVID-19 needs a big science approach. https://science.sciencemag.org/content/367/6485/1407
Zheng M., Song L. Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV. Cell. Mol. Immunol. 2020. 17(5): 536–538. DOI: https://doi.org/10.1038/s41423-020-0385-z
Achenbach J. The coronavirus isn’t mutating quickly, suggesting a vaccine would offer lasting protection. https://www.washingtonpost.com/health/the-coronavirus-isnt-mutating-quickly-suggesting-a-vaccine-would-offer-lasting-protection/2020/03/24/406522d6-6dfd-11ea-b148-e4ce3fbd85b5_story.html
Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus. https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-interim-phase-1-data-its-mrna-vaccine
Funk C.D., Laferriere C., Ardakani A. A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic. Front. Pharmacol. 2020. 11:937. DOI: https://doi.org/10.3389/fphar.2020.00937
Cohen J. Vaccine designers take first shots at COVID-19. Science. 2020. 368(6486): 14–16. DOI: https://doi.org/10.1126/science.368.6486.14
Callaway E. The race for coronavirus vaccines: a graphical guide. Nature. 2020. 580: 576-577. DOI: https://doi.org/10.1038/d41586-020-01221-y
Gao Q., Bao L., Mao H. et al. Rapid development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020. 369(6499): eabc1932. DOI: https://doi.org/10.1126/science.abc1932
Mueller S., Stauft C.B., Kalkeri R. et al. A codon-pair deoptimized live-attenuated vaccine against respiratory syncytial virus is immunogenic and efficacious in non-human primates. Vaccine. 2020. 38(14): 2943–2948. DOI: https://doi.org/10.1016/j.vaccine.2020.02.056
Yu J., Tostanoski L.H., Peter L. et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020. 20 May 2020: eabc6284. DOI: https://doi.org/10.1126/science.abc6284
Draft landscape of COVID-19 candidate vaccines. WHO. https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines
Oxford COVID-19 vaccine to begin phase II/III human trials. http://www.ox.ac.uk/news/2020-05-22-oxford-covid-19-vaccine-begin-phase-iiiii-human-trials
Lauerman J. Oxford, AstraZeneca Begin Advanced Trials of Covid Vaccine. Bloomberg. 22 May 2020. https://www.bloomberg.com/news/articles/2020-05-22/oxford-astrazeneca-begin-advanced-trials-of-covid-vaccine
Folegatti P.M., Ewer K.J., Aley P.K., et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet. 20 July, 2020. DOI: https://doi.org/10.1016/S0140-6736(20)31604-4
Zhu F.-C., Li Y.-H., Gua X.-H. et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020. 395: 1845–1854. DOI: https://doi.org/10.1016/S0140-6736(20)31208-3
Haseltine W.A. Lessons for COVID-19 from the Early Days of AIDS. Scientific American. July 6, 2020.https://www.scientificamerican.com/article/lessons-for-covid-19-from-the-early-days-of-aids/
Accelerating a safe and effective COVID-19 vaccine. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/accelerating-a-safe-and-effective-covid-19-vaccine
Draft landscape of COVID-19 candidate vaccines. WHO. 21 July, 2020. https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines
Ramesh S. Can BCG vaccine protect against Covid-19? Here’s why the excitement needs to be tempered. https://theprint.in/science/can-bcg-vaccine-protect-against-covid-19-heres-why-the-excitement-needs-to-be-tempered/401449/
Sparber S. Texas A&M researchers hope tuberculosis vaccine might prevent coronavirus deaths. https://www.krgv.com/news/texas-aandm-researchers-hope-tuberculosis-vaccine-might-prevent-coronavirus-deaths/
Brook B., Harbeson D.J., Shannon C.P. et al. BCG vaccination-induced emergency granulopoiesis provides rapid protection from neonatal sepsis. Sci. Transl. Med. 2020. 12(542): eaax4517. DOI: https://doi.org/10.1126/scitranslmed.aax4517
Arts R.J.W., Moorlag S.J.C.F.M., Novakovic B., Li Y., Wang S.Y., Oosting M., Kumar V., Xavier R.J., Wijmenga C., Joosten L.A.B., Reusken C.B.E.M., Benn C.S., Aaby P., Koopmans M.P., Stunnenberg H.G., van Crevel R., Netea M.G. BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity. Cell Host Microbe. 2018. 23(1): 89–100.e5. DOI: https://doi.org/10.1016/j.chom.2017.12.010
A $10M Grant Enables BCG Vaccine Trial to Expand Internationally, Enrol 10,000 Healthcare Workers. https://www.combacte.com/press-releases/11244/
Chumakov K., Benn C.S., Aaby P., Kottilil Sh., Gallo R. Can existing live vaccines prevent COVID-19? Science. 2020. 368(6496): 1187–1188. DOI: https://doi.org/0.1126/science.abc4262
Escobar L.E., Molina-Cruz A., Barillas-Mury C.BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). PNAS. 2020. 117(30): 17720–17726. DOI: https://doi.org/10.1073/pnas.2008410117
Hamiel U., Kozer E., Youngster I. SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults. JAMA. 2020. 323(22): 2340–2341. DOI: https://doi.org/10.1001/jama.2020.8189
Woodley M. Healthcare workers trial TB vaccine for coronavirus protection. newsGP. 27 Mar 2020. https://www1.racgp.org.au/newsgp/clinical/healthcare-workers-to-trial-tuberculosis-vaccine-f
Kramer A.E. Decades-Old Soviet Studies Hint at Coronavirus Strategy. https://www.nytimes.com/2020/06/24/world/europe/vaccine-repurposing-polio-coronavirus.html
Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/Imperial-College-COVID19-NPI-modelling-16-03-2020.pdf
Yang Y.Q., Sun Q., Wang Y.X., et al. Epidemic situation analysis and trend forecast of New Coronavirus Pneumonia (NCP) in Chongqing (in Chinese). Journal of Chongqing Normal University (Natural Science). 2020. 37(1). DOI: https://doi.org/10.1101/2020.02.17.20024034
Brovchenko I. Development of the mathematical model of Covid-19 epidemic spread in Ukraine. Svitohliad. 2020. 2(82): 2–14. (in Ukrainian). https://www.mao.kiev.ua/biblio/jscans/svitogliad/svit-2020-15-2/svitoglyad-2020-2-2-brovchenko.pdf
National coronavirus response: A road map to reopening. https://www.aei.org/research-products/report/national-coronavirus-response-a-road-map-to-reopening/
European countries are easing quarantine restrictions. http://lowcostavia.com.ua/europe-poslablyuye-karantynni-obmezhennya/
Prime Minister Denys Shmyhal unveils a step-by-step quarantine exit plan. Government of Ukraine. Official website. April 24, 2020. https://www.kmu.gov.ua/en/news/premyer-ministr-denis-shmigal-predstaviv-poetapnij-plan-znyattya-obmezhen
Ukrayina perekhodyt do nastupnoho etapu poslablennya karantynu. Ukrayinska pravda. June 1, 2020. (in Ukrainian). https://www.pravda.com.ua/news/2020/06/1/7253960/
Leshner A. Restart science stronger after COVID-19. Science. 2020. 369(6502): 262. DOI: https://doi.org/10.1126 / science.abd5780
